Evaluation of change in adipose and muscle layer thickness for Fat Burn

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
New Jersey Plastic Surgery (NJPS), Montclair, NJ
Fat Burn
BTL-899 - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study will evaluate the clinical efficacy and performance of the BTL-899 device for changes in subcutaneous fat and muscle tissue in the lateral abdomen region (also referred to as flanks or "love handles"). The study is a prospective, multi-center, open-label, single-arm study. The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 4 months

4 months
Evaluation of change in adipose and muscle layer thickness
Subject Satisfaction

Trial Safety

Trial Design

1 Treatment Group

Evaluation of change in adipose and muscle layer thickness
1 of 1
Experimental Treatment

46 Total Participants · 1 Treatment Group

Primary Treatment: Evaluation of change in adipose and muscle layer thickness · No Placebo Group · N/A

Evaluation of change in adipose and muscle layer thickness
Device
Experimental Group · 1 Intervention: BTL-899 · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BTL-899
2017
N/A
~360

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 months
Closest Location: New Jersey Plastic Surgery (NJPS) · Montclair, NJ
2022First Recorded Clinical Trial
1 TrialsResearching Fat Burn
1 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are of child-bearing potential.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.